Australia Gene Therapy Market Size & Outlook, 2023-2030
- Biotechnology
- Gene Expression & Gene Therapy
- Gene Therapy Market Outlook
- Gene Expression & Gene Therapy
Australia Gene Therapy Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the gene therapy market
Australia gene therapy market highlights
- The Australia gene therapy market generated a revenue of USD 95.8 million in 2023 and is expected to reach USD 246.2 million by 2030.
- The Australia market is expected to grow at a CAGR of 14.4% from 2024 to 2030.
- In terms of segment, lentivirus was the largest revenue generating vector type in 2023.
- Lentivirus is the most lucrative vector type segment registering the fastest growth during the forecast period.
Gene therapy market data book summary
| Market revenue in 2023 | USD 95.8 million |
| Market revenue in 2030 | USD 246.2 million |
| Growth rate | 14.4% (CAGR from 2024 to 2030) |
| Largest segment | Lentivirus |
| Fastest growing segment | Lentivirus |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Lentivirus, Modified Herpes Simplex Virus, Other Vector Type |
| Key market players worldwide | Regenxbio Inc, Oxford Biomedical Research, Bristol-Myers Squibb Co, Sanofi SA, Ultragenyx Pharmaceutical Inc, Roche Holding AG ADR, Bluebird bio Inc, Novartis AG ADR, UniQure NV, Cellectis SA, Sangamo Therapeutics Inc, Benitec Biopharma Inc, SiBiono GeneTech, Transgene SA, Gensight Biologics SA, Astellas Pharma Inc |
Other key industry trends
- In terms of revenue, Australia accounted for 1.1% of the global gene therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan gene therapy market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 246.2 million by 2030.
With rising development efforts in Australia, the market is likely to witness increased demand for gene therapies. For instance, in January 2022, the NSW government announced leveraging gene therapy expertise to establish a commercial-scale viral vector manufacturing facility in the country.
Similarly, in May 2019, Therapeutic Innovation Australia (TIA) invested USD 8.8 million in gene therapy facilities across Australia.
Numerous clinical studies in gene therapies are ongoing or have already been completed in the country, which have the potential to transform the treatment of various diseases, including cancer. Furthermore, the commercial availability of products, such as Kymriah and Imlygic, is anticipated to drive the country’s revenue share in the coming years.
Key Regions:U.S., UK, Japan, South Korea, China
No credit card required*
Publish Date: Mar 17, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gene Therapy Market Scope
Gene Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| UniQure NV | View profile | 480 | Paasheuvelweg 25, Amsterdam, NH, Netherlands, 1105 BP | www.uniqure.com |
| SiBiono GeneTech | View profile | 1001-5000 | Shenzhen, Guangdong, China, Asia | www.sibiono.com |
| Cellectis SA | View profile | 216 | 8, rue de la Croix Jarry, Paris, France, 75013 | www.cellectis.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | www.bluebirdbio.com |
| Sangamo Therapeutics Inc | View profile | 405 | 501 Canal Boulevard, Richmond, CA, United States, 94804 | www.sangamo.com |
Australia Gene Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Gene Therapy Market Outlook will help companies and investors design strategic landscapes.
Lentivirus was the largest segment with a revenue share of 70.04% in 2023.
Horizon Databook has segmented the Australia gene therapy market based on lentivirus, modified herpes simplex virus, other vector type covering the revenue growth of each sub-segment from 2018 to 2030.
With rising development efforts in Australia, the market is likely to witness increased demand for gene therapies. For instance, in January 2022, the NSW government announced leveraging gene therapy expertise to establish a commercial-scale viral vector manufacturing facility in the country.
Similarly, in May 2019, Therapeutic Innovation Australia (TIA) invested USD 8.8 million in gene therapy facilities across Australia.
Numerous clinical studies in gene therapies are ongoing or have already been completed in the country, which have the potential to transform the treatment of various diseases, including cancer. Furthermore, the commercial availability of products, such as Kymriah and Imlygic, is anticipated to drive the country’s revenue share in the coming years.
- Australia Gene Therapy Market Vector Type Outlook (Revenue, USD Million , 2018-2030)
- Lentivirus
- AAV
- RetroVirus & gamma RetroVirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-viral Plasmid Vector
- Other Vector Type
- Australia Gene Therapy Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-cell Lymphoma
- ADA-SCID
- Melanoma (lesions)
- Beta-Thalassemia Major/SCD
- Head & Neck Squamous Cell Carcinoma
- Peripheral arterial disease
- Spinal Muscular Atrophy (SMA)
- Others
Reasons to subscribe to Gene Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Gene Therapy Market Outlook databook
- Our clientele includes a mix of Gene Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Gene Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Gene Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Australia Gene Therapy Market, 2018-2030 (US$M)
Australia gene therapy market statistics, by vector type, 2018-2030 (US$M)
